Literature DB >> 25332520

JAK2 (V617F) Positive Latent Myeloproliferative Neoplasm Presenting with Splanchnic Vein Thrombosis.

Amandeep Salhotra1, Thein H Oo2.   

Abstract

Myeloproliferative neoplasms (MPNs) are chronic clonal hematopoietic stem cell disorders characterized by proliferation of one or more of the granulocytic, red cell or platelet lineages in the bone marrow, with fairly normal maturation, resulting in increase in the leukocyte, erythrocytes and platelets in the blood. They also represent a common cause of splanchnic vein thrombosis (SVT). Herein, we describe a case of SVT as a presenting symptom of latent MPN. The patient has had normal complete blood counts since presentation. 3 ½ years later, she was found to have JAK2 (V617F) mutation and bone marrow biopsy was consistent with MPN. Five years later, her platelet count started to rise. In patients with a first episode of SVT, thrombophilia workup including JAK2 (V617F) mutation is warranted. Anticoagulation with heparin and warfarin is the treatment of choice for SVT.

Entities:  

Year:  2012        PMID: 25332520      PMCID: PMC4192237          DOI: 10.1007/s12288-012-0215-2

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  33 in total

1.  The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia.

Authors:  Betty Cheung; Deepti Radia; Panagiotis Pantelidis; Ghasem Yadegarfar; Claire Harrison
Journal:  Br J Haematol       Date:  2006-01       Impact factor: 6.998

2.  Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome.

Authors:  Donatella Colaizzo; Lucio Amitrano; Giovanni L Tiscia; Luigi Iannaccone; Anna Gallone; Elvira Grandone; Maria A Guardascione; Maurizio Margaglione
Journal:  Blood Coagul Fibrinolysis       Date:  2008-07       Impact factor: 1.276

3.  The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.

Authors:  Ayalew Tefferi; Terra L Lasho; Susan M Schwager; Jacob S Strand; Michelle Elliott; Ruben Mesa; Chin-Yang Li; Martha Wadleigh; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer       Date:  2006-02-01       Impact factor: 6.860

4.  The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.

Authors:  D Colaizzo; L Amitrano; G L Tiscia; G Scenna; E Grandone; M A Guardascione; V Brancaccio; M Margaglione
Journal:  J Thromb Haemost       Date:  2006-10-20       Impact factor: 5.824

5.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

Review 6.  Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis.

Authors:  V De Stefano; L Teofili; G Leone; J J Michiels
Journal:  Semin Thromb Hemost       Date:  1997       Impact factor: 4.180

7.  Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.

Authors:  Raj K Patel; Nicholas C Lea; Michael A Heneghan; Nigel B Westwood; Dragana Milojkovic; Murugaiyan Thanigaikumar; Deborah Yallop; Roopen Arya; Antonio Pagliuca; Joop Gäken; Julia Wendon; Nigel D Heaton; Ghulam J Mufti
Journal:  Gastroenterology       Date:  2006-06       Impact factor: 22.682

8.  The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.

Authors:  C Goulding; B Uttenthal; L Foroni; V Duke; A Traore; P Kottaridis; A V Hoffbrand; D Patch; C McNamara
Journal:  Int J Lab Hematol       Date:  2008-10       Impact factor: 2.877

9.  JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis.

Authors:  Francesco Dentali; Alessandro Squizzato; Lorenza Brivio; Lorena Appio; Leonardo Campiotti; Mark Crowther; Anna Maria Grandi; Walter Ageno
Journal:  Blood       Date:  2009-03-09       Impact factor: 22.113

10.  The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly.

Authors:  W D Kniffin; J A Baron; J Barrett; J D Birkmeyer; F A Anderson
Journal:  Arch Intern Med       Date:  1994-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.